Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

When will generic fiasap insulin be available?
Quartette side effects?
Guselkumab loss of exclusitivy?
Atorvastatin side effects heart palpitations?
Is it okay to take anti histamine when on statins?

Pembrolizumab generic?

See the DrugPatentWatch profile for Pembrolizumab

Pembrolizumab – “Generic” status

Region Status What you’ll see on the label Key points
United States (FDA) Biosimilar approved (not a “generic” in the classic sense) Generic name: pembrolizumab
Brand name of biosimilar: pembrolizumab (often sold under a brand name chosen by the manufacturer; the original brand is Keytruda)		 – The biosimilar is biochemically equivalent to Keytruda for the same indications.
– It must have the same amino‑acid sequence, similar structure, and comparable safety/efficacy profile.
– Prescribers decide when to switch; no automatic substitution at the pharmacy level.
European Union Biosimilar approved Generic name: pembrolizumab
Brand name varies by manufacturer		 – EU regulators have a similar “biosimilarity” pathway.
– Biosimilars may be interchangeable, but local national pharmacy rules apply.
Other countries Variable Some countries (e.g., Canada, Japan) have approved biosimilars with their own brand names; others have no biosimilar yet. Check local drug‑approval agencies for the most up‑to‑date status.

Why the term “generic” is a bit misleading

  • Monoclonal antibodies are biologics, not small‑molecule drugs. Because they’re produced in living cells, they can’t be exactly “copy‑cat” copies; instead, they are biosimilars.
  • The FDA (and EMA, etc.) require comparability studies that prove no clinically meaningful differences in safety, purity, or potency.
  • Once approved, a biosimilar is still marketed under its generic name (pembrolizumab), but it will usually carry a distinct brand name that reflects the manufacturer.

How it looks on your prescription

Label element Example
Drug name Pembrolizumab
Strength 200 mg/mL (or other concentration)
Brand (if biosimilar) Pembrolizumab (or the specific manufacturer’s brand)
Manufacturer e.g., Mirogen, BMS, etc.
Route IV infusion

Practical take‑away for patients

  1. Ask your oncologist whether a biosimilar is an appropriate alternative for your specific cancer and treatment plan.
  2. Insurance coverage: Many plans now cover the biosimilar as the preferred option because of lower cost, but you’ll need the prescriber’s authorization.
  3. Switching: If you are already on Keytruda, your doctor will decide whether a switch to a biosimilar is safe. Most biosimilars are considered interchangeable, but it’s not automatic.
  4. Side‑effect profile: The biosimilar carries the same risk of immune‑related adverse events (e.g., colitis, pneumonitis, thyroiditis). Monitor for these just as you would with Keytruda.
  5. Monitoring: Labs and imaging follow the same schedule as with the original drug.

Bottom line

  • Pembrolizumab is currently not a classic generic; instead, a biosimilar has been approved (in the U.S. and many other markets).
  • It keeps the same generic name, pembrolizumab, but may be sold under a different brand name.
  • If you’re considering a cost‑saving alternative, ask your healthcare team if a biosimilar is available and appropriate for you.

Feel free to let me know if you need specific information about a biosimilar brand available in your country, or if you have questions about insurance coverage, side‑effect monitoring, or dosing schedules.



Other Questions About Pembrolizumab :

pembrolizumab loss of exclusivity Can you identify the protein receptor targeted by pembrolizumab? Pembrolizumab england patent? Pembrolizumab brand name? Which pd 1 receptor is pembrolizumab s binding site? Pembrolizumab patente? What type of receptor is targeted by pembrolizumab?